BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29216889)

  • 1. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
    Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
    J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
    Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
    J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
    Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
    J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity.
    Minopoli M; Polo A; Ragone C; Ingangi V; Ciliberto G; Pessi A; Sarno S; Budillon A; Costantini S; Carriero MV
    Sci Rep; 2019 Aug; 9(1):12169. PubMed ID: 31434916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
    Carriero MV; Bifulco K; Ingangi V; Costantini S; Botti G; Ragone C; Minopoli M; Motti ML; Rea D; Scognamiglio G; Botti G; Arra C; Ciliberto G; Pessi A
    Sci Rep; 2017 May; 7(1):1312. PubMed ID: 28465589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface.
    Gorrasi A; Li Santi A; Amodio G; Alfano D; Remondelli P; Montuori N; Ragno P
    PLoS One; 2014; 9(1):e86352. PubMed ID: 24466048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.
    Yousif AM; Minopoli M; Bifulco K; Ingangi V; Di Carluccio G; Merlino F; Motti ML; Grieco P; Carriero MV
    PLoS One; 2015; 10(5):e0126172. PubMed ID: 25938482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.
    de Paulis A; Montuori N; Prevete N; Fiorentino I; Rossi FW; Visconte V; Rossi G; Marone G; Ragno P
    J Immunol; 2004 Nov; 173(9):5739-48. PubMed ID: 15494526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
    Bifulco K; Longanesi-Cattani I; Franco P; Pavone V; Mugione P; Di Carluccio G; Masucci MT; Arra C; Pirozzi G; Stoppelli MP; Carriero MV
    PLoS One; 2012; 7(9):e44806. PubMed ID: 23049759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
    Ingangi V; Bifulco K; Yousif AM; Ragone C; Motti ML; Rea D; Minopoli M; Botti G; Scognamiglio G; Fazioli F; Gallo M; De Chiara A; Arra C; Grieco P; Carriero MV
    Oncotarget; 2016 Aug; 7(34):54474-54487. PubMed ID: 27323409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
    Stahl A; Mueller BM
    Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.
    Montuori N; Bifulco K; Carriero MV; La Penna C; Visconte V; Alfano D; Pesapane A; Rossi FW; Salzano S; Rossi G; Ragno P
    Cell Mol Life Sci; 2011 Jul; 68(14):2453-67. PubMed ID: 20972812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.
    Margheri F; Luciani C; Taddei ML; Giannoni E; Laurenzana A; Biagioni A; ChillĂ  A; Chiarugi P; Fibbi G; Del Rosso M
    Oncotarget; 2014 Mar; 5(6):1538-53. PubMed ID: 24681666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.
    Yousif AM; Ingangi V; Merlino F; Brancaccio D; Minopoli M; Bellavita R; Novellino E; Carriero MV; Carotenuto A; Grieco P
    Eur J Med Chem; 2018 Jan; 143():348-360. PubMed ID: 29202399
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Napolitano F; Rossi FW; Pesapane A; Varricchio S; Ilardi G; Mascolo M; Staibano S; Lavecchia A; Ragno P; Selleri C; Marone G; Matucci-Cerinic M; de Paulis A; Montuori N
    Front Immunol; 2018; 9():574. PubMed ID: 29670612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
    Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
    Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.